

Analytical profile of the lysergamide 1cP-AL-LAD and detection of impurities

Pierce V. Kavanagh,¹ Folker Westphal,² Benedikt Pulver,^{2,3,4} Hannes M. Schwelm,^{3,4} Alexander Stratford,⁵ Volker Auwärter,³ Stephen J. Chapman,⁶ Adam L. Halberstadt^{7,8} Simon D. Brandt^{9,*}

¹ Department of Pharmacology and Therapeutics, School of Medicine, Trinity Centre for Health Sciences, St. James Hospital, Dublin 8, Ireland

² State Bureau of Criminal Investigation Schleswig-Holstein, Section Narcotics/Toxicology, Mühlenweg 166, D-24116 Kiel, Germany

³ Institute of Forensic Medicine, Forensic Toxicology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

⁴ Hermann Staudinger Graduate School, University of Freiburg, Freiburg, Germany.

⁵ Synex Synthetics BV, Karveelweg 20, 6222NH, Maastricht, The Netherlands

⁶ Isomer Design, 4103-210 Victoria Street, Toronto, ON, M5B 2R3, Canada


⁷ Department of Psychiatry, University of California San Diego, La Jolla, CA 92093-0804, USA

⁸ Research Service, VA San Diego Healthcare System, San Diego, CA 92161, USA


⁹ School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool L3 3AF, UK

* Correspondence to: Simon D. Brandt, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street, Liverpool, L3 3AF, UK. E-Mail: s.brandt@ljmu.ac.uk


Content	Page
Proposed EI-MS fragmentation pathways (1cP-AL-LAD)	S3–S4
GC-MS XIC traces (powdered sample of 1cP-AL-LAD) including GC-induced artifacts	S5
Proposed EI-MS fragmentation pathways for 1cP-AL-LAD-A (-C ₂ H ₆)	S6
Proposed EI-MS fragmentation pathways (1cP-AL-LAD isomer)	S7
Proposed ESI-QTOF-MS/MS fragmentation pathways for 1cP-AL-LAD	S8
LC-QTOF-MS/MS trace of 1cP-AL-AL-LAD (powdered sample) and comparison with AL-LAD and 1P-AL-LAD standards	S9
Additional tandem mass spectra recorded in full scan/AutoMS/MS mode (powdered sample) and some tentative identifications	S10–S15
Peak at 10.2 min (1cP-AL-LAD powdered sample) following LC-QTOF-MS/MS analysis and tentative identification as dimethyldibenzylidene sorbitol (DBS), a plastics additive.	S16
Proposed ESI-QTOF-MS/MS fragmentation pathways for DBS	S17
Detection of 1P-AL-LAD in methanolic blotter extract (LC-ion trap-MS; XIC & GC-MS; XIC)	S18
LC-MS analysis results involving contaminated 1cP-AL-LAD blotters posted anonymously on the Internet	S19
1D/2D NMR data for 1cP-AL-LAD	S20–S43




Proposed EI-MS fragmentation pathways (1cP-AL-LAD)




Proposed EI-MS fragmentation pathways (1cP-AL-LAD)




GC-MS XIC traces (powdered sample of 1cP-AL-LAD) including GC-induced artifacts




Proposed EI-MS fragmentation pathways for 1cP-AL-LAD-A (-C₂H₆)





Proposed EI-MS fragmentation pathways (1cP-AL-LAD isomer)




Proposed ESI-QTOF-MS/MS fragmentation pathways



LC-QTOF-MS/MS trace of 1cP-AL-AL-LAD (+bbCID MS/MS; 10 µg/mL 1cP-AL-LAD powder) and comparison with AL-LAD and 1P-AL-LAD standards





AL-LAD standard at 5.6 min (+bbCID MS; 1 µg/mL)





1P-AL-LAD standard at 7.0 min (+bbCID MS; 1 µg/mL)


Additional tandem mass spectrum recorded in full scan/AutoMS/MS mode (powdered sample) and tentative identification




Additional tandem mass spectra recorded in full scan/AutoMS/MS mode (powdered sample)




Additional tandem mass spectrum recorded in full scan/AutoMS/MS mode (powdered sample) and tentative identification





Additional tandem mass spectrum recorded in full scan/AutoMS/MS mode (powdered sample)






Additional tandem mass spectrum recorded in full scan/AutoMS/MS mode (powdered sample) and tentative identification




Additional tandem mass spectrum recorded in full scan/AutoMS/MS mode (powdered sample) and tentative identification



Peak at 10.2 min (1cP-AL-LAD powdered sample) following LC-QTOF-MS/MS analysis and tentative identification as dimethyldibenzylidene sorbitol (DBS), a plastics additive, presumably detected as part of the analytical procedure.




Proposed ESI-QTOF-MS/MS fragmentation pathways for DBS




Detection of 1P-AL-LAD in methanolic blotter extract (10 blotters)

LC-ion trap-MS; XIC $[M+H]^+$ at m/z 406




GC-MS; XIC $[M^+]$ at m/z 405



Supporting Information – Drug Testing and Analysis

LC-MS analysis results involving contaminated 1cP-AL-LAD blotters posted anonymously on the Internet (https://pdfhost.io/v/qq9z.MDx6_Bad_blotter_report.pdf)





**High quality blotters with standard design
from the major lysergamide lab**

D 1P-LSD 1P-LSD 1P-LSD 1P-LSD 1P-LSD
-LSD 1P-LSD 1P-LSD 1P-LSD 1P-LSD 1P-LSD 1P-LSD
1P-AL-LAD 1cP-AL-LAD 1cP-AL-
AD 1cP-AL-LAD 1cP-AL-LAD


Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
 ^1H -NMR (700 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
 ^1H -NMR (700 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
 ^1H -NMR (700 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
 ^1H -NMR (700 MHz)
 d_6 -DMSO




1cP-AL-LAD (including impurities)
 ^1H -NMR (700 MHz)
 d_6 -DMSO



^1H -NMR (600 MHz)
 d_6 -DMSO


Supporting Information – Drug Testing and Analysis

1cP-AL-LAD before prep TLC
 ^1H -NMR (700 MHz, DMSO-d₆)




UV 254 nm UV 366 nm
(Chloroform/methanol, 9/1)

1cP-AL-LAD after prep TLC
 ^1H -NMR (600 MHz, DMSO-d₆)




UV 254 nm UV 366 nm
(Chloroform/methanol, 9/1)




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
COSY (700 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
COSY (700 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis




Supporting Information – Drug Testing and Analysis


1cP-AL-LAD (including impurities)
COSY (700 MHz)
 d_6 -DMSO



Supporting Information – Drug Testing and Analysis





Supporting Information – Drug Testing and Analysis



Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
 ^{13}C -NMR (175 MHz)
 $\text{d}_6\text{-DMSO}$




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)



^{13}C -NMR DEPTQ (150 MHz)

d_6 -DMSO




Supporting Information – Drug Testing and Analysis



1cP-AL-LAD before prep TLC
 ^{13}C -NMR (150 MHz, DMSO-d₆)



Cyclopropanecarboxylic acid
 ^{13}C -NMR (150 MHz, DMSO-d₆)




1cP-AL-LAD after prep TLC
 ^{13}C -NMR (150 MHz, DMSO-d₆)




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HSQC (700/175 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HSQC (700/175 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HSQC (700/175 MHz)
 d_6 -DMSO



Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HSQC (700/175 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)


HMBC (700/175 MHz)

d₆-DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HMBC (700/175 MHz)
 d_6 -DMSO



Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HMBC (700/175 MHz)
 d_6 -DMSO




Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)

HMBC (700/175 MHz)

d₆-DMSO



Supporting Information – Drug Testing and Analysis

1cP-AL-LAD (including impurities)
HMBC (700/175 MHz)
 d_6 -DMSO

